Sanofi, Regeneron fall after late-stage data for COPD therapy

1 day ago 1
COPD medical concept. Wooden cubes with the inscription "COPD - chronic obstructive pulmonary disease", stethoscope. Beautiful wooden background. Copy space.

Dzmitry Dzemidovich

Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease (COPD).

Based on

Recommended For You

More Trending News

Read Entire Article